Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial.

Al‐Batran, Salah‐Eddin; Homann, Nils; Schmalenberg, Harald; Kopp, Hans‐Georg; Martin Haag, Georg; Barbara Luley, Kim; Schmiegel, Wolff; Folprecht, Gunnar; Probst, Stephan; Prasnikar, Nicole; Thuss‐Patience, Peter; Fischbach, Wolfgang; Trojan, Jörg; Koenigsmann, Michael; Pauligk, Claudia; Oliver Goetze, Thorsten; Jaeger, E.; Meiler, Johannes; Schüler, Martin; Hofheinz, Ralf‐Dieter

doi:10.1200/jco.2017.35.15_suppl.4004

Public

Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial.

Published in Journal of Clinical Oncology • May 20, 2017

Authors:

Salah‐Eddin Al‐Batran

Nils Homann

Harald Schmalenberg

Abstract

4004 Background: The MAGIC trial established perioperative (periop) epirubicin, cisplatin, and 5-FU (ECF) as a standard treatment for patients (pts) with operable esophagogastric cancer, but survival continues to remain poor. FLOT4 (NCT01216644) is a multicenter, randomized, investigator-initiated, ...

Subject

Epirubicin

Docetaxel

Medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!